The active C-terminal decapeptide of kisspeptin that potently activates GnRH neurons to stimulate the hypothalamic-pituitary-gonadal axis for reproductive and hormonal effects.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Kisspeptin-10 is the smallest biologically active fragment of the kisspeptin family — a group of neuropeptides encoded by the KISS1 gene that were originally characterized as metastasis suppressors before researchers realized they were also master regulators of human reproduction. The “10” designation refers to the ten-amino-acid C-terminal sequence (Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-amide) that retains full biological activity at the GPR54 receptor, now formally renamed KISS1R.
The story of kisspeptin’s discovery is a rare example of serendipity in molecular biology. The KISS1 gene was first identified in Hershey, Pennsylvania — hence the name — by researchers mapping tumor suppressor loci in melanoma. For nearly a decade, kisspeptin was studied almost exclusively in oncology. It was not until 2003, when two independent research groups simultaneously published findings that loss-of-function mutations in GPR54 caused idiopathic hypogonadotropic hypogonadism in both mice and humans, that the reproductive biology world took notice. The peptide’s role as the master switch for the reproductive hormonal axis rapidly became one of the most intensively studied areas in neuroendocrinology.
What makes kisspeptin-10 particularly interesting from a research standpoint is that it sits at an extraordinary anatomical and physiological crossroads. Kisspeptin neurons in the arcuate nucleus and the anteroventral periventricular nucleus receive signals from metabolic sensors, circadian clocks, stress pathways, and gonadal steroid feedback loops — then translate all of that information into a single output: the decision to fire or not fire a pulse of GnRH into the hypothalamic-pituitary portal circulation. In that sense, kisspeptin-10 is not just a hormone; it is the biological gatekeeper of the entire reproductive axis.
The decapeptide form is preferred in research settings because its small size allows reasonable synthetic yields, acceptable plasma stability relative to shorter analogs, and a well-characterized receptor binding profile. Kisspeptin-10 has a plasma half-life of roughly 28 minutes in humans, making it short-lived enough to mimic pulsatile physiology when administered in discrete doses, yet long enough to produce measurable endocrine responses in controlled studies. For researchers exploring reproductive disorders, puberty timing, and infertility treatment alternatives, kisspeptin-10 represents both a precision tool and a window into the fundamental architecture of mammalian reproduction.
You can explore how kisspeptin-10 compares to other reproductive peptides in the Peptide Database, or use the dosage calculators to model research protocols.
Kisspeptin-10 exerts all of its reproductive effects by binding with high affinity (Ki in the low nanomolar range) to the KISS1 receptor, a seven-transmembrane G-protein-coupled receptor previously known as GPR54. Upon binding, KISS1R couples primarily to the Gq/11 family of heterotrimeric G-proteins, triggering phospholipase C-beta (PLC-β) activation. PLC-β then cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes calcium from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). The resulting calcium transient depolarizes the GnRH neuron, driving the burst firing that releases GnRH into the portal blood. Importantly, KISS1R also couples to Gα12/13 and Gαs subunits in certain cell contexts, meaning the downstream signaling is more nuanced than a single pathway — though the calcium mobilization arm appears dominant for acute LH release.
GnRH neurons in the hypothalamus express KISS1R at extraordinarily high levels, which makes them exquisitely sensitive to kisspeptin-10. When the peptide binds, the resulting calcium influx and sodium channel opening drive a prolonged, high-frequency burst of action potentials that propagates to axon terminals in the median eminence. This triggers a bolus release of GnRH into the hypophyseal portal capillaries. Anterior pituitary gonadotroph cells detect this GnRH pulse and respond by synthesizing and secreting luteinizing hormone (LH) and follicle-stimulating hormone (FSH) into the systemic circulation. LH then acts on Leydig cells in the testes to drive testosterone biosynthesis, or on ovarian theca cells to support estradiol production and the preovulatory LH surge. FSH simultaneously drives Sertoli cell function and follicular development. The entire cascade from kisspeptin-10 binding to measurable LH in peripheral blood occurs within 15–30 minutes in human studies, making the system remarkably fast for a neuroendocrine axis.
One of the most elegant features of the kisspeptin system is its role in sculpting the pulsatile pattern of GnRH — and therefore LH — secretion. In the arcuate nucleus, kisspeptin neurons co-express neurokinin B (NKB) and dynorphin A, forming what researchers call the KNDy neuron network. NKB acts as an autocrine/paracrine signal that synchronizes the bursting of KNDy neurons, amplifying the kisspeptin pulse; dynorphin terminates the burst, creating the inter-pulse interval. This internal oscillator generates approximately one GnRH pulse per 60–90 minutes in healthy adults. Estradiol and testosterone exert negative feedback by suppressing kisspeptin neuron activity in the arcuate nucleus, while the anteroventral periventricular nucleus kisspeptin neurons mediate positive estradiol feedback in females — the neural basis for the preovulatory LH surge. Understanding pulsatile vs. tonic administration of kisspeptin-10 is therefore critical for research design, because chronic tonic exposure can desensitize KISS1R and paradoxically suppress rather than stimulate the axis.
One of the most clinically impactful research applications of kisspeptin-10 is its use as a diagnostic probe in pediatric and adolescent endocrinology. Idiopathic hypogonadotropic hypogonadism (IHH) and Kallmann syndrome (IHH with anosmia) present a diagnostic challenge: how does a clinician determine whether a patient with delayed or absent puberty has a hypothalamic defect, a pituitary defect, or a transient constitutional delay? The kisspeptin-10 stimulation test offers a partial answer. Because kisspeptin acts upstream of GnRH, a robust LH response to kisspeptin-10 implies intact GnRH neurons and a functional pituitary, pointing toward a hypothalamic defect rather than a structural pituitary failure. Research groups at King’s College London published landmark work demonstrating that adults with IHH who retain a GnRH neuron population show significant LH responses to kisspeptin-10 infusion, while patients with complete neuronal loss do not. More recently, investigators have explored whether kisspeptin-10 challenge can predict reversibility of hypogonadism — patients who respond robustly may have a higher probability of spontaneous reproductive recovery — though this application remains investigational. The test has also been explored in adolescents with constitutional delay, where the ability to detect nascent GnRH neuron activation earlier than traditional endocrine testing could guide timing of therapeutic interventions.
Perhaps the most immediately translatable research application of kisspeptin-10 is as an alternative trigger for final oocyte maturation in assisted reproductive technology. Standard IVF protocols use an injection of human chorionic gonadotropin (hCG) to trigger the ovulatory LH surge approximately 36 hours before oocyte retrieval. While effective, hCG carries a risk of ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening complication characterized by vascular leakage, ascites, and in severe cases, thrombosis. Because kisspeptin-10 works by stimulating the body’s own LH surge rather than delivering an exogenous LH-like signal, the resulting LH pattern may be more physiological and of shorter duration — theoretically reducing OHSS risk. A series of trials led by Professor Waljit Dhillo at Imperial College London demonstrated that kisspeptin-10 successfully triggered oocyte maturation in women undergoing IVF, with fertilization and pregnancy rates comparable to hCG in standard-risk patients. A subsequent randomized controlled trial in high-risk (OHSS-prone) patients found a strikingly low rate of severe OHSS with kisspeptin-10 versus hCG. Ongoing work is refining optimal doses, exploring kisspeptin analogs with longer half-lives, and evaluating outcomes in frozen embryo transfer cycles, where the kisspeptin trigger may offer advantages for endometrial receptivity.
In men with hypogonadotropic hypogonadism — a condition where insufficient LH and FSH from the pituitary leads to low testosterone and impaired spermatogenesis — kisspeptin-10 has been investigated as both a diagnostic and a potential therapeutic agent. Research published in the Journal of Clinical Investigation demonstrated that pulsatile intravenous administration of kisspeptin-10 to men with IHH produced dose-dependent LH pulses and, with sustained administration, meaningful increases in peripheral testosterone. The ability to restore testicular function by working through the body’s own gonadal axis, rather than replacing testosterone directly, is significant because it preserves spermatogenesis — a major limitation of exogenous testosterone therapy. Men who receive exogenous testosterone experience suppression of the entire HPG axis, rendering them infertile during treatment. A kisspeptin-based approach, if successfully translated, could simultaneously address hypogonadal symptoms and preserve fertility potential. Challenges remain around delivery (pulsatile IV infusion is not clinically practical), but longer-acting kisspeptin analogs under development may eventually bridge this gap.
Functional hypothalamic amenorrhea (FHA) is a reversible suppression of GnRH pulsatility driven by energy deficit, psychological stress, or excessive exercise. It is a leading cause of infertility in women of reproductive age and represents a particularly compelling target for kisspeptin-10 research because the GnRH neuron population remains structurally intact — it is simply under-stimulated by a suppressed kisspeptin tone. Preclinical models have consistently shown that kisspeptin administration restores GnRH pulsatility in energy-restricted animals. Human studies are more limited but supportive: women with hypothalamic amenorrhea show LH responses to kisspeptin-10 challenge, though often blunted compared to normally cycling controls, reflecting downregulation of KISS1R. Restoring pulsatile kisspeptin signaling in this population has been proposed as a more physiological approach to ovulation induction compared to pulsatile GnRH pump therapy, which bypasses the kisspeptin layer entirely. Research is ongoing to determine whether short-course kisspeptin-10 administration can “prime” the GnRH neuron network and restore spontaneous pulsatility after treatment ends.
Kisspeptin’s influence extends well beyond the hypothalamus. KISS1R is expressed in the amygdala, hippocampus, septum, and olfactory regions — brain areas central to emotion, memory, and social behavior. Preclinical research using kisspeptin-10 has revealed that KISS1R activation in the amygdala reduces fear responses and anxiety-like behavior in rodents, suggesting a role in stress modulation that is independent of gonadal steroid effects. Human neuroimaging research has shown that peripheral kisspeptin-10 infusion in healthy men increases bold signal responses to sexual stimuli and olfactory cues in limbic regions, while simultaneously decreasing responses to negative emotional stimuli. These findings raise the intriguing possibility that kisspeptin signaling evolved not just to regulate fertility but to coordinate the full suite of reproductive behaviors — attraction, mate assessment, and reduced fear necessary for approach behavior. Researchers have proposed exploring kisspeptin-10 in conditions characterized by impaired sexual function or social withdrawal, though this remains highly preliminary.
Given that the KISS1 gene was first characterized as a metastasis suppressor, research into kisspeptin-10’s oncological properties has a long history — though the picture is considerably more complex than early studies suggested. In cell line models, kisspeptin-10 inhibits migration, invasion, and colony formation in melanoma, breast, prostate, and thyroid cancer cells. The proposed mechanism involves KISS1R-mediated activation of focal adhesion kinase (FAK) signaling and cytoskeletal rearrangement that reduces cell motility. Some studies have also reported pro-apoptotic effects. However, paradoxical tumor-promoting effects have been observed in other cancer types and model systems, suggesting that the receptor expression context matters enormously. Clinical translation remains distant, but the basic science literature on kisspeptin-10 as an oncological tool continues to grow, particularly in the context of neuroendocrine tumors where KISS1/KISS1R expression patterns may have prognostic value.
The dosing of kisspeptin-10 in human research studies varies considerably by application. For acute LH stimulation tests designed to assess HPG axis integrity, single intravenous bolus doses of 0.3–10 nmol/kg body weight have been used, with doses around 1–3 nmol/kg producing robust and reliable LH responses in most subjects. In IVF trigger protocols, the Imperial College group employed single subcutaneous doses ranging from 1.6 to 12.8 nmol/kg, finding that 6.4 nmol/kg provided the most consistent oocyte maturation trigger in standard-risk patients. For pulsatile infusion protocols intended to restore LH pulsatility in IHH, doses of 0.1–0.4 nmol/kg delivered every 90 minutes via subcutaneous pump have been studied. It is critical to note that these are investigational protocols from controlled clinical studies, not clinical guidelines, and all research use should be conducted under appropriate institutional and regulatory oversight.
Intravenous and subcutaneous routes have both been explored in human research. IV administration produces the most rapid and quantifiable LH response, making it preferred for diagnostic stimulation tests where precise pharmacokinetics matter. Subcutaneous administration has been validated for IVF trigger and pulsatile infusion protocols, offering practical advantages for outpatient research settings. The peptide’s amidated C-terminus and the absence of a free carboxyl group confer modest resistance to serum carboxypeptidases, but plasma half-life remains short at approximately 28 minutes for native kisspeptin-10, reinforcing that delivery timing relative to endpoints (e.g., oocyte retrieval 36 hours post-trigger) must be carefully controlled.
This distinction is arguably the most important consideration in kisspeptin-10 research design. The physiological mode of kisspeptin secretion is pulsatile, synchronized with GnRH pulses. Continuous or high-frequency administration leads to KISS1R desensitization and receptor internalization, paradoxically suppressing LH secretion — an effect analogous to GnRH agonist-induced downregulation. Research in hypogonadal animals and humans has demonstrated that pulsatile delivery (one pulse per 60–90 minutes) sustains LH responses over days, while continuous infusion causes initial stimulation followed by suppression. This biology makes kisspeptin-10 a nuanced research tool: for studies aimed at stimulating the axis, pulse timing must replicate the physiological inter-pulse interval. Automated subcutaneous pump systems have been used in longer-duration human studies to achieve this precision.
Lyophilized kisspeptin-10 peptide used in research is typically reconstituted in sterile 0.9% saline or sterile water at concentrations appropriate for the intended route and volume. Stock solutions are generally stable for 2–4 weeks at 4°C and longer periods at −20°C when protected from freeze-thaw cycling. The peptide is sensitive to proteolytic degradation at physiological temperature, so reconstituted solutions should be prepared close to the time of use and not stored at room temperature for extended periods. Research-grade material should meet standard purity benchmarks (typically ≥95% by HPLC) with mass spectrometric confirmation of molecular weight and sequence identity.
Human studies of kisspeptin-10 have generally reported a favorable acute safety profile. In IVF trigger studies involving hundreds of participants, the most commonly reported adverse events were mild and transient injection-site reactions. No severe anaphylactic or systemic inflammatory reactions attributable to the peptide have been reported in the published clinical trial literature. Transient nausea has been occasionally noted at higher IV doses. Because kisspeptin-10 stimulates endogenous LH release rather than introducing exogenous gonadotropins, the hormonal perturbations are self-limited by pituitary reserve and gonadal feedback mechanisms. In women undergoing IVF, the primary safety advantage over hCG is the substantially reduced risk of severe OHSS — observed in multiple trial cohorts — which is itself a major source of IVF-related morbidity.
Despite the encouraging short-term safety data, important gaps remain in the safety knowledge base for kisspeptin-10. Long-duration pulsatile administration studies in humans are limited, and the consequences of prolonged KISS1R stimulation on receptor regulation, pituitary function, and bone density (which depends in part on sex steroids) are not fully characterized. The oncological dual nature of kisspeptin signaling — suppressive in some tumor types, potentially promotional in others — means that kisspeptin-10 administration in patients with undiagnosed malignancies carries theoretical concern, though this has not been observed clinically. Central effects (mood, cognition, stress responses) observed at pharmacological doses in research settings could also carry implications for populations vulnerable to psychiatric disorders, and dedicated safety studies in these groups have not been conducted.
Research use of kisspeptin-10 is generally contraindicated in pregnancy, given that kisspeptin signaling changes dramatically during gestation and exogenous administration could theoretically disrupt placentation or trigger premature labor — though the evidence base here is limited. Patients with hormone-sensitive malignancies (e.g., hormone receptor-positive breast or prostate cancer) would require careful ethical consideration before inclusion in kisspeptin-10 research protocols, given the peptide’s potent sex-steroid-stimulating effects. As with all peptide research reagents, researchers should ensure material is sourced from qualified suppliers with documented GMP compliance, sterility testing, and endotoxin certification before any human or animal in vivo use. Use the AI Coach for protocol design guidance.
No. Kisspeptin-54 (also called metastin) is the full-length 54-amino-acid peptide derived from the KISS1 precursor protein. Kisspeptin-10 is the C-terminal decapeptide fragment that retains full KISS1R-binding activity because the receptor recognition sequence lies within that ten-residue segment. Both bind the same receptor with comparable affinity, but kisspeptin-10’s smaller size makes it easier to synthesize, and its pharmacokinetic profile is slightly different. Most human research studies have used kisspeptin-10 or kisspeptin-54 depending on availability and the specific research question; direct comparative pharmacodynamic studies suggest broadly similar acute LH responses at equimolar doses.
In intravenous bolus studies, LH begins rising within 15 minutes of administration and typically peaks between 30 and 60 minutes. The response is dose-dependent within the ranges studied. Subcutaneous administration produces a slightly delayed and potentially more prolonged LH peak, consistent with the slower absorption kinetics. The absolute magnitude of the LH response varies considerably between individuals and depends on baseline HPG axis function, age, sex, and menstrual cycle phase in women.
In research settings, pulsatile kisspeptin-10 administration has been shown to stimulate LH pulsatility and downstream testosterone production in men with hypogonadotropic hypogonadism. However, this requires functional GnRH neurons and a responsive pituitary — conditions not met in primary hypogonadism (testicular failure) or severe pituitary damage. It is not an approved therapeutic for testosterone deficiency, and men with primary hypogonadism would not respond because the axis defect is downstream of where kisspeptin acts.
The key proposed advantage is a lower risk of ovarian hyperstimulation syndrome (OHSS). hCG has a very long half-life (days) and directly stimulates ovarian LH receptors, producing a prolonged gonadotropin effect that can trigger OHSS in susceptible patients. Kisspeptin-10 triggers the body’s own LH surge, which is physiologically self-limited by feedback mechanisms and shorter in duration. Clinical trial data support this hypothesis in high-risk populations, though head-to-head randomized trials in broader populations are still ongoing.
Research in humans using brain imaging has found that kisspeptin-10 infusion modifies limbic system responses to emotional and sexual stimuli, generally in a direction of reduced negative affect and enhanced responses to sexual cues. Whether these effects are direct (via central KISS1R) or indirect (via the sex steroids that kisspeptin stimulates) remains an open question. No clinically significant mood adverse events were reported in IVF trials, though these were not designed to detect subtle neurological endpoints.
Kisspeptin-10 is not measured on standard clinical hormone panels. However, the downstream effects of kisspeptin-10 administration — elevated LH, FSH, and sex steroids — would be readily apparent on standard reproductive hormone panels. Research studies have used specialized ELISA-based kisspeptin immunoassays to measure circulating kisspeptin levels, but these assays are not routinely available in clinical laboratories.
Chronic pulsatile administration (mimicking physiological timing) appears to sustain LH stimulation over multi-day infusion periods in human studies, with some evidence of maintained testosterone levels. In contrast, continuous or high-frequency administration leads to receptor desensitization and paradoxical gonadotropin suppression. Long-term human safety data beyond a few weeks of pulsatile administration is limited, and the long-term effects on KISS1R regulation, pituitary sensitivity, and the reproductive axis have not been fully characterized in extended studies.
Published research protocols from the Imperial College London group and other academic centers are available in peer-reviewed journals including the Journal of Clinical Investigation, Journal of Clinical Endocrinology and Metabolism, and Human Reproduction. For structuring your own research parameters, the Peptides Helper calculators can assist with dose modeling, and the AI Coach provides literature-grounded protocol guidance.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.